Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2022 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: technetium who wrote (190)	9/30/2022 1:38:38 PM
From: tamborelli	Read Replies (1) \| Respond to of 267

What I think you're missing on CBIO is that they paid out a fat dividend of $1.43 per share. The drop in stock price (as far as I can tell) was associated with the ex-dividend date. ir.catalystbiosciences.com

To: technetium who wrote (190)

10/3/2022 12:23:08 PM

From: technetium

2 Recommendations

Recommended By
BulbaMan
Lance Bredvold

Read Replies (1) | Respond to of 267

Another week of bad week in the markets, and I was steeling myself for the fourth straight week cueing those sad, sad, trombones… But… I should have looked at the spread sheet.

Yah, sure, the NASDAQ Composite shed -2.7% for the week, typical for the other broad indices as well. But the Biotech indices were good news, the S&P Biotech Index up +3.6%. And this seemed a pretty broad move for the sector, with 116 out of the 190 stocks chosen by the contest participants in the Black.

Looking at the individual entries we see some very good news. And it is, in fact, real news, not someone at Motley Fool talking a stock up.

Instead, finally big moves from stocks as a result of a science event:

BIOA-B.ST was the top stock for the last week, doubling. At first I thought, oh, another reverse stock split. But 2 for 1 is really not a likely split. What I found was:
Lecanemab phase 3 Clarity AD study in early Alzheimer’s disease meets primary and all key secondary endpoints with high statistical significance
marketwatch.com

This was enough to move BIOA-B.ST up to third place in YTD performance (+85%).And then also in second place, XFOR up +86%.X4 Pharma Highlights New Data Supporting Mavorixafor's Broad Potential In Chronic Neutropenia
HROW is up 51%, because a key product is hitting distribution.

As far as the rest, maybe it was just some end of the quarter enthusiasm. Some stocks *did* lose. Yep, there’s my old zombie friend GNCA.
Moving to the portfolio performance, we see an increase in the portfolio average of +2.4%. The median also up +1.7%. The best performing portfolio for the week, JFM WINTER up +28%! (No prize for guessing who was the sole investor in BIOA-B.ST among the contestants). HORESINALFALFA in third place for the week (+7.4%), which bumped them up to 7th in the YTD performance, the only change in the relative standings in the top 10, other than JACK HARTMANN’s return, with only a one week absence.

With the end of the quarter, this contest is moving into the home stretch. Another three months to go. Still lots of opportunities for interesting results. Stay tuned.

		Report Time Ranges
			From	To
		Recent	9/23/22	9/30/22
		YTD	12/31/21	9/30/22
Index Performance
			Symbol	Recent	YTD
			^IXIC	-2.69%	-32.40%
			^NBI	2.05%	-20.33%
			^SPSIBI	3.62%	-29.05%
Share Performance
Recent				YTD
Top 5		Bottom 5		Top 5		Bottom 5
BIOA-B.ST	207.240%	GNCA	-22.164%	OPTN	125.93%	GNCA	-98.98%
XFOR	85.829%	OCUL	-21.550%	CBIO	109.71%	VLON	-95.23%
HROW	51.064%	ACHL	-20.423%	BIOA-B.ST	85.63%	PTE	-94.07%
BIIB	34.998%	STSA	-18.033%	FENC	84.09%	RNLX	-91.95%
PLXP	24.712%	PRDS	-14.747%	RVNC	65.44%	PLXP	-91.89%
			Top 10 Portfolio YTD		YTD(Portfolio - SPSIBI)	Rec	Rec(Port. - SPSIBI)
			DIEGOSAN	-3.88%	25.18%	0.514%	-3.110%
			DEW DILIGENCE	-10.91%	18.14%	3.142%	-0.482%
			TECHNETIUM	-15.14%	13.92%	3.580%	-0.044%
			BIOSCIENTISTSA	-24.14%	4.92%	1.802%	-1.823%
			BRENDAN_49	-26.80%	2.26%	-0.281%	-3.906%
			GENEGURU	-26.99%	2.06%	1.632%	-1.993%
			HORSEINALFALFA	-27.11%	1.94%	7.356%	3.731%
			ROCKY9	-27.35%	1.70%	2.030%	-1.595%
			A.J. MULLEN	-29.01%	0.05%	0.682%	-2.942%
			JACK HARTMANN	-33.27%	-4.22%	3.776%	0.152%
Average and Median Portfolio Performance
	Avg Recent	Avg YTD	Median Recent		Median YTD
	$1,342	-39.42%	ETHAN H	$1,079	JFM WINTER	-38.57%
	2.41%	-39.42%	GENEGURU	1.678%	JFM WINTER	-38.57%

To: technetium who wrote (190)

10/9/2022 2:35:29 PM

From: technetium

1 Recommendation

Recommended By
BulbaMan

Read Replies (1) | Respond to of 267

So, after last week’s pretty good, this week we shouldn’t expect much, right? This week instead has turned out to be … variable. The stock indices tell this story: The NASDAQ composite eked out a modest gain, +0.7%, after all the excitement in the early part of the week. But the S&P Biotech Index took a hit of -0.3%. On the other hand the NASDAQ Biotech Index outperformed its broader brethren, up +1.2%.

Looking at the individual issues, the top end showed real gains: IMVT up +63% of the week, (because of a new public offering, equal to 10% of the current equity); PRVB up +54% because of signing a marketing/developing agreement with another company for its lead investigational drug candidate (i.e. currently unapproved); and AUTL is up +45% because it is licensing a chunk of its IP to Bristol-Myers-Squibb. At least there are reasons for the moves out in the open. The big loser, KALV (-66%), had announced the termination of a Phase II “reevaluation” study on Tuesday. In terms of YTD performance, last week’s top five just shuffled a bit between themselves, ditto for the bottom 5.

The contest portfolios were generally significantly better than the indices, up +4.4% on average (+3.5% for the median). Only ten portfolios were in the red for the week. Interestingly only one of the top 10 YTD portfolios were among the big winners for the week, BULBAMAN, up 15.3%, to rejoin the list after a three week absence. The gap between the first and second place YTD portfolios, DIEGOSAN and DEW DILIGENCE, has been narrowing over the last few weeks from 9.2% to this weeks 5.2%. Still a horse race.

		Report Time Ranges
			From	To
		Recent	9/30/22	10/7/22
		YTD	12/31/21	10/7/22
Index Performance
			Symbol	Recent	YTD
			^IXIC	0.73%	-31.91%
			^NBI	1.17%	-19.39%
			^SPSIBI	-0.31%	-29.27%
Share Performance
Recent				YTD
Top 5		Bottom 5		Top 5		Bottom 5
IMVT	62.903%	KALV	-65.886%	CBIO	122.73%	GNCA	-99.38%
PRVB	53.778%	BBLG	-44.743%	OPTN	113.58%	PTE	-95.06%
AUTL	44.860%	VSTM	-42.941%	BIOA-B.ST	81.43%	VLON	-94.93%
EYEN	40.153%	GNCA	-38.983%	RVNC	79.96%	PLXP	-92.63%
MYOV	38.697%	SNWV	-29.217%	FENC	76.82%	ATHX	-92.58%
			Top 10 Portfolio YTD		YTD(Portfolio - SPSIBI)	Rec	Rec(Port. - SPSIBI)
			DIEGOSAN	-4.05%	25.22%	-0.185%	0.121%
			DEW DILIGENCE	-9.21%	20.06%	1.915%	2.221%
			TECHNETIUM	-12.84%	16.43%	2.706%	3.012%
			BIOSCIENTISTSA	-20.18%	9.09%	5.213%	5.519%
			HORSEINALFALFA	-23.25%	6.02%	5.297%	5.603%
			ROCKY9	-23.91%	5.36%	4.738%	5.044%
			GENEGURU	-24.60%	4.67%	3.276%	3.581%
			BRENDAN_49	-25.23%	4.04%	2.143%	2.448%
			BULBAMAN	-26.80%	2.47%	15.307%	15.612%
			A.J. MULLEN	-27.29%	1.98%	2.420%	2.726%
Average and Median Portfolio Performance
	Avg Recent	Avg YTD	Median Recent		Median YTD
	$2,285	-37.13%	ECCU	$1,911	JFM WINTER	-39.16%
	4.35%	-37.13%	GENEGURU	3.534%	JFM WINTER	-39.16%